Below is a timeline which illustrates the over 40 years of clinical data on etifoxine and the evolution of GRX-917.

September 2018

May 2018

Compared etifoxine to lorazepam (Ativan®) – for alertness and cognitive functions in elderly patients

May 17, 2018|

Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet

November 2015

Safety Profile of Etifoxine: A French Pharmacovigilance Survey

November 13, 2015|

Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse or pharmacodependance were reported.

January 2015

March 2009

January 2006

Compared etifoxine to lorazepam (Ativan®) – established non-inferiority in adjustment disorder with anxiety ADWA

January 19, 2006|

Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin

April 2005

March 2001

Compared etifoxine with lorazepam (Ativan®) – for sedative and amnesic effects

March 29, 2001|

A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects J. Micallef, C. Soubrouillarda, F. Gueta, M. E. Le Guernb, C. Alquierb, B. Bruguerollea, O. Blin

January 1985

January 1979

Etifoxine Approved for Anxiety in France

January 1, 1979|

A small French distributor developed etifoxine for anxiety in France under the tradename Stresam and subsequently distributed the product throughout Eastern Europe, South America, South Africa and other small regions.

April 1969

Hoechst Discovers Etifoxine

April 13, 1969|

Etifoxine was developed by Hoechst of Germany in the 1960s. It was originally believed to be a mild benzodiazepine, because it didn’t sedate and scientists at the time did not have the technology to measure its true efficacy or determine its actual mechanism of action. Accordingly, it was deemed non-competitive with the drugs of the time, like Valium, and therefore never introduced into the United States.